The Business of Fashion
Agenda-setting intelligence, analysis and advice for the global fashion community.
Agenda-setting intelligence, analysis and advice for the global fashion community.
Famille C Participations, the investment company owned by the Courtin family, announced on Tuesday that it has made a €130 million ($141 million) investment to acquire a strategic stake in luxury hotel brand Evok Collection.
In addition to the family’s ownership of Clarins, Famille C has invested in Pai Skincare, Ilia Beauty, Ceremonia and Joone, as well as tech companies such as Launchmetrics.
“We are very excited about this new commitment, which furthers our work in beauty and well being and embodies our ambition for the French art of living,” said Prisca Courtin, managing director of Famille C Participations, in a statement.
Famille C is focused on investing in hotel companies that “create unique experiences focused on well-being.”
ADVERTISEMENT
The investment includes a partnership with Evok Collection to open Clarins Spa locations in its hotels. Other hotels with Clarins Spa locations include Hotel Mont-Blanc Chamonix and Miraval Resort & Spa in Arizona.
Founded in 2014, Evok Collection is a hotel company under Zaka Investissement, the real estate company owned by businessman Pierre Bastid. The company owns and operates six addresses in Paris and Venice, with two additional hotels planned in Madrid and Rome. The goal from the new investment is to reach 15 hotels within five years.
Learn more:
Courtin-Clarins Family to Acquire Clean Makeup Brand Ilia
Ilia founder Sasha Plasvic and chief executive Lynda Berkowitz will continue to lead the business and retain a minority share.
Guerlain really wants to win this game.
The battle for exclusive international beauty launches is intensifying as Nykaa, Tira and more set their eyes on expansion.
As in-person retail continues to recover, store owners and marketers are working hard to press the main advantage analogue shopping has over digital: its appeal to all the senses.
What had once been a nimble, innovative company, Neutrogena became slow-moving and cautious. It retreated precisely when rivals went all in – and missed out on a big chunk of the market.